Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.
The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) are secreted postprandially and contribute importantly to postprandial glucose tolerance. In this study, we assessed the individual and combined contributions of endogenous GIP and GLP-1 to the postprandial changes in glucose and glucoregulatory hormones using the novel GIP receptor antagonist GIP(3-30)NH2 and the well-established GLP-1 receptor antagonist exendin(9-39)NH2. During 4-h oral glucose tolerance tests (75 g) combined with an ad libitum meal test, 18 healthy men received on four separate days in randomized, double-blinded order intravenous infusions of A) GIP(3-30)NH2 (800 pmol/kg/min) plus exendin(9-39)NH2 (0–20 min: 1,000 pmol/kg/min; 20–240 min: 450 pmol/kg/min), B) GIP(3-30)NH2, C) exendin(9-39)NH2, and D) saline, respectively. Glucose excursions were significantly higher during A than during B, C, and D, while glucose excursions during B were higher than during C and D. Insulin secretion (assessed by C-peptide/glucose ratio) was reduced by 37 ± 16% (A), 30 ± 17% (B), and 8.6 ± 16% (C) compared with D (mean ± SD). A and C resulted in higher glucagon levels and faster gastric emptying. In conclusion, endogenous GIP affects postprandial plasma glucose excursions and insulin secretion more than endogenous GLP-1, but the hormones contribute additively to postprandial glucose regulation in healthy individuals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Glucose-dependent insulinotropic polypeptide is the primary incretin hormone responsible for mealstimulated insulin secretion in healthy individuals.7”
From Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes (2022) · cites this paper as [7]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 1×
“A lack of effect of exendin(9-39) NH2 on food consumption has been reported in previous studies (42,43) and could be due to simultaneously increased levels of peptide YY (10,30,34,37), stimulating satiety (44).”
BackgroundReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 8×
“Study Design Each participant served as his own control and attended four 75-g OGTTs on four separate study days in a randomized order with infusion of GIP(3-30)NH2 (260 min at a rate of 800 pmol/kg/min), exendin(9-39)NH2 (20 min at 1,000 pmol/kg/min followed by 240 min at 450 pmol/ kg/min), GIP(3-30)NH2 and exendin(9…”
BackgroundMethodInfluentialTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Göke, R., Fehmann, H. C., Linn, T., Schmidt, H., Krause, M., Eng, J., & Göke, B. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36565-2 · Cited by 837
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Self-citationSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578 · cited 2×
“5A and Table 2]), may contribute to explain the lack of effect of exendin(9-39)NH2 on typical GLP-1 effects such as food intake and insulin secretion as previously described (31,43,48).”
Background
Research works printed but not linked: 2
- Pacini, 2005, The insulinogenic index is a valid marker of beta cell function in different metabolic categories, Diabetes, 54, A370
- Bergmann, 2017, The effects of GIP/GLP-1 receptor co-activation on appetite and food intake in overweight/obese subjects, Diabetologia, 60, S5
Cited by
Items 101–192 of 192
Gabe, M. B. N., Gasbjerg, L. S., Gadgaard, S., Lindquist, P., Holst, J. J., & ROSENKILDE, M. M. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15866 · Cited by 14
Self-citationInter-relationships between gastric emptying and glycaemia: Implications for clinical practice
Murthy, T. A., Chapman, M. J., Jones, K. L., Horowitz, M., & Marathe, C. S. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.447 · Cited by 17
Holst, J. J., Madsbad, S., Bojsen-Møller, K. N., Dirksen, C., & Svane, M. S. (2024) · Peptides · doi:10.1016/j.peptides.2024.171199 · Cited by 18
Self-citationLewandowski, S. L., EL, K. M., & Campbell, J. E. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00360.2023 · Cited by 16
Dalle, S., & Abderrahmani, A. (2024) · Cells · doi:10.3390/cells13151244 · Cited by 18
Khawaji, A., A. Jaly, A., A. Bakri, H., Ravi, R., Hattan, A., Khawaji, A., & Najmi, W. (2025) · Journal of Obesity · doi:10.1155/jobe/3442754 · Cited by 13
“GIP is a hormone produced by the K cell in the intestine that stimulates glucose-dependent insulin secretion from the pancreas [18].”
InfluentialRoell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
The naturally occurring GIP(1-30)NH2 is a GIP receptor agonist in humans
Krogh, L. S. L., Henriksen, K., Stensen, S., Skov‐Jeppesen, K., Bergmann, N. C., Størling, J., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., Gasbjerg, L. S., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac015 · Cited by 13
Self-citationUsui, R., Hamamoto, Y., Imura, M., Omori, Y., Yamazaki, Y., Kuwata, H., Tatsuoka, H., Shimomura, K., Murotani, K., Yamada, Y., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16086 · Cited by 16
A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity
Samms, R. J., & Sloop, K. W. (2025) · Diabetes · doi:10.2337/dbi24-0026 · Cited by 27
Douros, J. D., Mowery, S. A., & Knerr, P. J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113812 · Cited by 12
Sundaresan, S., Johnson, C., Dixon, K. B., Dole, M., Kilkelly, D. M., Antoun, J., Flynn, C. R., Abumrad, N. N., & Tamboli, R. A. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.06.011 · Cited by 12
Rasmussen, R. S., Langberg, L. S., Østergaard, F., Nielsen, S. W., Vestergaard, M. B., Skov‐Jeppesen, K., Hartmann, B., Johannesen, H. H., Holst, J. J., Haddock, B., et al. (2025) · Diabetes · doi:10.2337/db25-0149 · Cited by 13
Self-citationMaagensen, H., Helsted, M. M., Gasbjerg, L. S., Vilsbøll, T., & Knop, F. K. (2022) · Current Osteoporosis Reports · doi:10.1007/s11914-022-00767-2 · Cited by 16
Self-citationSemaglutide-Mediated Lithium Toxicity
Onggo, S., Chang, R., Marlett, J., Zimmerman, A., Bettencourt, H., Hughes, T., & Hah, M. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002017 · Cited by 12
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
Marathe, C. S., Pham, H., Marathe, J., Trahair, L. G., Huynh, L. Q., Wu, T., Phillips, L. K., Rayner, C. K., Nauck, M. A., Horowitz, M., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01461-z · Cited by 11
Preinfalk, V., Kimmeswenger, I., Somoza, V., & Lieder, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30329 · Cited by 10
α cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion
Cui, C., Leander, D. C., Gray, S. M., EL, K. M., Chen, A. Y., Grimsrud, P. A., Becker, J. O., Taylor, A. J., Zhang, G., Sloop, K. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady8048 · Cited by 15
The Location of Missense Variants in the Human GIP Gene Is Indicative for Natural Selection
Lindquist, P., Gasbjerg, L. S., Mokrosiński, J., Holst, J. J., Hauser, A. S., & ROSENKILDE, M. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891586 · Cited by 11
Self-citationIncretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
Alicic, R. Z., & Neumiller, J. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010201 · Cited by 16
Le, T. T. B., Minh, L. H. N., Devi, P., Islam, N., & Sachmechi, I. (2024) · Cureus · doi:10.7759/cureus.51460 · Cited by 20
Tirzepatide a novel anti diabetic molecule unfold dual action
Sweta, Gupta, S., Bansal, S., Devi, S., Sharma, S., Laxmi, L., & Deepa (2024) · Discover Public Health · doi:10.1186/s12982-024-00200-2 · Cited by 14
The evolution of the therapeutic concept ‘GIP receptor antagonism’
Koefoed-Hansen, F., Helsted, M. M., Kizilkaya, H. S., Lund, A., ROSENKILDE, M. M., & Gasbjerg, L. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1570603 · Cited by 9
Self-citationGut physiology meets microbiome science
Daniel, H. (2022) · Gut Microbiome · doi:10.1017/gmb.2022.10 · Cited by 9
Acarbose diminishes postprandial suppression of bone resorption in patients with type 2 diabetes
Dalsgaard, N. B., Gasbjerg, L. S., Helsted, M. M., Hansen, L. S., Hansen, N. L., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023) · Bone · doi:10.1016/j.bone.2023.116687 · Cited by 10
Self-citationJensen, M., Gasbjerg, L. S., Skov‐Jeppesen, K., Jacobsen, J. C., Poulsen, S. S., Zhou, C., Jakubauskaite, R., Poulsen, F. R., Bonde, C., Albarazi, M., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae583 · Cited by 8
Self-citationLorza‐Gil, E., Strauß, O., Ziegler, E., Kansy, K., Katschke, M.-T., Rahimi, G., Neuscheler, D., Sandforth, L., Sandforth, A., Sancar, G., et al. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102067 · Cited by 12
Tordrup, E. K., Gadgaard, S., Windeløv, J. A., Holst, J. J., Gasbjerg, L. S., Hartmann, B., & ROSENKILDE, M. M. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116893 · Cited by 7
Self-citationRodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
He, X., Zhao, Z., Sun, Y., & Jiang, X. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118163 · Cited by 8
Cardiovascular effects of tirzepatide
Sumithran, P., Russell, A. W., & Zoungas, S. (2025) · Journal of Endocrinology · doi:10.1530/joe-24-0259 · Cited by 12
Anti‐incretin effect: The other face of Janus in human glucose homeostasis
Karras, S. Ν., Koufakis, T., Mustafa, O. G., & Kotsa, K. (2019) · Obesity Reviews · doi:10.1111/obr.12917 · Cited by 7
Incretins in the Therapy of Diabetic Kidney Disease
Przezak, A., Bielka, W., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212312 · Cited by 7
Duodenal enteroendocrine cells and GIP as treatment targets for obesity and type 2 diabetes
Bailey, C. J., & Flatt, P. R. (2024) · Peptides · doi:10.1016/j.peptides.2024.171168 · Cited by 6
Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management
Rabbani, S. A., El‐Tanani, M., Matalka, I. I., Rangraze, I. R., Aljabali, A. A. A., Khan, M. A., & Tambuwala, M. M. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2395540 · Cited by 9
Subramanian, V., Sherman, A., Holst, J. J., Knop, F. K., Vilsbøll, T., & Bagger, J. I. (2025) · Diabetologia · doi:10.1007/s00125-025-06524-1 · Cited by 6
Self-citationDemidova, T. Y., & Izmaylova, M. Y. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-03 · Cited by 8
Sosibo, A. M., Mzimela, N. C., Ngubane, P. S., & Khathi, A. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-024-01363-z · Cited by 5
Chai, S., Zhang, R., Carr, R. D., Deacon, C. F., Zheng, Y., Rajpathak, S. N., Chen, J., & Yu, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203187 · Cited by 8
Hædersdal, S., Lund, A., Nielsen-Hannerup, E., Maagensen, H., Forman, J. L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0291 · Cited by 6
Self-citationA Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues
Sicinski, K. M., Sürmeli, D., Du, J., Raman, V. S., Montanari, V., Lee, M., Harwood, B. N., Kopin, A. S., Beinborn, M., & Kumar, K. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00111 · Cited by 7
Osonoi, T., Tamasawa, A., Osonoi, Y., Ofuchi, K., Katoh, M., & Saito, M. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00689-w · Cited by 6
Utzschneider, K. M., Tripputi, M., Butera, N. M., Mari, A., Rosin, S. P., Banerji, M. A., Bergenstal, R. M., Brown, N. M., Carlson, A. L., DeFronzo, R. A., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2419 · Cited by 5
Kahles, F., Rau, M., Reugels, M., Foldenauer, A. C., Mertens, R. W., Arrivas, M. C., Schröder, J. H., Idel, P., Moellmann, J., van der Vorst, E. P. C., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01454-3 · Cited by 5
Lauritsen, J. V., Bergmann, N. C., Junker, A. E., Gyldenløve, M., Skov, L., Gluud, L. L., Hartmann, B., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad161 · Cited by 4
Self-citationÅhrén, B. (2023) · Biomedicines · doi:10.3390/biomedicines11020591 · Cited by 5
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Wiley eBooks · doi:10.1002/9781119824701.ch09 · Cited by 6
Krogh, L. S. L., Helsted, M. M., Englund, A., Bergmann, N. C., Skov‐Jeppesen, K., Nielsen, C. K., Hansen, C. P., ROSENKILDE, M. M., Hartmann, B., Holst, J. J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70186 · Cited by 3
Self-citationYokoyama, F., Yoshitsugu, R., Yamazaki, H., & Ishizuka, S. (2024) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.70.76 · Cited by 3
Rangwala, H. S., Fatima, H., Ali, M., Mustafa, M. S., Shafique, M. A., Rangwala, B. S., & Abbas, S. R. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01412-8 · Cited by 3
Holst, J. J. (2024) · The Journal of Physiology · doi:10.1113/jp287461 · Cited by 5
Self-citationAl‐Zaid, B., & Al‐Sabah, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1528295 · Cited by 5
Lobato, C. B., Pereira, S. S., Guimarães, M., Soares, B., Hartmann, B., Nora, M. C., Holst, J. J., & Monteiro, M. P. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01865-8 · Cited by 4
Self-citationDruzhilov, М. A., Kuznetsova, Т. Y., & Chumakova, G. A. (2021) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2022-4755 · Cited by 5
Xie, S., Chen, D., Cai, Y., Xu, L., Liao, O., Jia, X., Ji, X., Chen, H., Mao, J., & Cai, J. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.022 · Cited by 3
Tirzepatide in Treating Metabolic Disorders
Wei, S., & Xu, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100023 · Cited by 3
Altered GIP/GLP-1 Secretion Ratio is Associated With Impaired β Cell Function in Humans
Giuseppe, G. D., Gliozzo, G., Ciccarelli, G., Carciero, L., Brunetti, M., Soldovieri, L., Quero, G., Cinti, F., Nista, E. C., Lucia, S. S. D., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf210 · Cited by 3
Self-citationWest, J. A., Ghosh, S. S., Parkes, D. G., Tsakmaki, A., Grønlund, R. V., Pedersen, P. J., MAGGS, D. G., Rajagopalan, H., & Bewick, G. A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/822122 · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2024) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2024.09.003 · Cited by 3
From the Discovery of GLP-1 to Today’s Diabetes/Obesity Therapy and Beyond
Holst, J. J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.04.010 · Cited by 3
Self-citationStrategies for Long-Term Weight Loss and Maintenance
Seo, Y. B. (2023) · Korean Journal of Family Practice · doi:10.21215/kjfp.2023.13.3.128 · Cited by 2
Safety of native glucose-dependent insulinotropic polypeptide in humans
Helsted, M. M., Schaltz, N. L., Gasbjerg, L. S., Christensen, M., Vilsbøll, T., & Knop, F. K. (2024) · Peptides · doi:10.1016/j.peptides.2024.171214 · Cited by 3
Self-citationKammaripalle, T. K. C., Giordano, J., Rana, H., Gade, A. R., & Reddy, S. (2025) · Cureus · doi:10.7759/cureus.85366 · Cited by 4
TCF7 is not essential for glucose homeostasis in mice
Kaur, K. D., Wong, C. K., Baggio, L. L., Beaudry, J. L., Fuchs, S., Panaro, B. L., Matthews, D., Cao, X., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101213 · Cited by 2
Khan, Z., Naeem, M. O., Khan, S. K., Khan, F., Abdullah, M., Attique, I., Muhammad, S. D., & Amin, A. (2023) · Cureus · doi:10.7759/cureus.44314 · Cited by 3
Portha, B., Liu, J., Movassat, J., & Tourrel‐Cuzin, C. (2025) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.05.006 · Cited by 1
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2026.01.001 · Cited by 1
Clinical Potential of GIP in Type 2 Diabetes and Obesity
Nauck, M. A., Gribble, F. M., Reimann, F., D’Alessio, D. A., & Campbell, J. E. (2026) · Diabetes Care · doi:10.2337/dci25-0141 · Cited by 3
Impact of incretin analogues on lipid and lipoprotein metabolism in obesity and diabetes
Baragetti, A., & Norata, G. D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70483 · Cited by 1
Gao, S., & Borner, T. (2026) · Appetite · doi:10.1016/j.appet.2026.108723 · Cited by 2
A novel macroalgae protein concentrate attenuates postprandial glycaemia in healthy adults
Pavis, G. F., Whelehan, G., Egan, S. M., Noctor, E., Fitzgerald, R. J., Amigo‐Benavent, M., Norton, C., & Carson, B. P. (2026) · The Journal of Nutritional Physiology · doi:10.1016/j.jnphys.2026.100050 · Cited by 1
GLP-1 analogs: a comparison of new anti diabetic medications - presenting benefits and risks
Dębik, M., Szydłowski, Ł., Żurowska, K., Bednarski, A., Krużel, A., Ziajor, S., Sajdak, P., Tomasik, J. M., Stodolak, M., & Kłos, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.62.014 · Cited by 1
Бобров, Е. С., Gorbunova, A. Y., Sannikova, E. P., Gubaidullin, I. I., Ignatova, O. M., Kopaeva, M. Y., Bulushova, N. V., & Kozlov, D. G. (2022) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683822090034 · Cited by 1
Gorbunova, A. Y., Sannikova, E. P., Gubaidullin, I. I., Ignatova, O. M., Kopaeva, M. Y., Bulushova, N. V., & Kozlov, D. G. (2021) · Biotekhnologiya · doi:10.21519/0234-2758-2021-37-6-74-83
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Self-citationL’intestin un organe endocrine : de la physiologie aux implications thérapeutiques en nutrition
Beyec, J. L., Ledoux, S., Coëffier, M., & Gall, M. L. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2021.12.179 · Cited by 2
Tirzepatid mit doppeltem Wirkansatz
(2023) · Info Diabetologie · doi:10.1007/s15034-023-4580-8
Kopaeva, M. Y., Sannikova, E. P., Бобров, Е. С., Gubaidullin, I. I., Bulushova, N. V., & Kozlov, D. G. (2023) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683823090065 · Cited by 1
Zhu, J., Huang, Y., Luo, Y., Wen, Y., Li, H., Li, W., Deng, Y., Shao, J., Huang, H., & Zhu, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3894429/v1
Portha, B., & Liu, J. (2026) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2025.12.005 · Cited by 1
(2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33287-6.00006-5
Voigt, J. H., Zubanovic, N. B., Møller, A. B., Suwal, S., Andersen, U., Andersen, H. H., Rittig, N. F., & Søndergaard, E. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101647
Mallinson, J. E., Keeton, M., Nixon, A., Sheth, A., Jones, R., Pabla, P., Senden, J. M., van Loon, L. J. C., & Tsintzas, K. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101660
Vignera, S. L., Fioriglio, C., & Condorelli, R. A. (2026) · Diagnostics · doi:10.3390/diagnostics16131979
Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases
Chui, Z. S. W., Xue, Y., Wu, X., & Xu, A. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100150
Incretins: From Gene Expression to Secretion and Action of GLP-1 and GIP
Lobato, C. B., & Holst, J. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-11985-9.00004-4
Self-citationRivera‐Gonzalez, O., Liu, L., Gribble, F. M., Reimann, F., & Wess, J. (2026) · Science Advances · doi:10.1126/sciadv.aeb9805
Deru, L. S., Bailey, B. W., Hales, K. E., Gipson, E. Z., Merrill, R. M., & Bikman, B. T. (2026) · Nutrients · doi:10.3390/nu18162669 · Cited by 1
Chirapongsathorn, S., & Tacke, F. (2026) · Digestion · doi:10.1159/dig/acmag014
Liu, C., Wang, Y., Liu, J., Tian, P., Liu, J., Li, M., Zhang, Z., & Zhang, P. (2026) · Peptides · doi:10.1016/j.peptides.2026.171524
Metadata
- Authors
- Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., Holst, J. J., Rosenkilde, M. M., & Knop, F. K.
- Affiliations
- University of Copenhagen (DK)
- Gentofte Hospital (DK)
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Corresponding author
- Knop, Filip K.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2019-01-09
- Volume
- 68
- Issue
- 5
- Pages
- 906-917
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2909748938
- Semantic Scholar
- 8d259751958bd756f4a81231f9791af24dbcf3b4
- Cited by
- 193
- References
- 52
- Citations by year
- 2026: 17 · 2025: 28 · 2024: 34 · 2023: 21 · 2022: 25 · 2021: 26 · 2020: 18 · 2019: 24
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Funders
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretins, postprandial glucose regulation, GIP receptor antagonist, exendin-9-39, insulin secretion, glucagon, gastric emptying, oral glucose tolerance test, healthy men
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucagon, Glucose, Glucose Tolerance Test, Humans, Infusions, Intravenous, Male, Peptide Fragments, Receptors, Gastrointestinal Hormone, Postprandial Period, Glucagon-Like Peptide 1, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.